Leerink Partnrs cut shares of HilleVax (NASDAQ:HLVX – Free Report) from a strong-buy rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for HilleVax’s Q2 2024 earnings at ($0.82) EPS, Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($2.46) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.21) EPS and FY2027 earnings at ($1.42) EPS.
Other research analysts also recently issued reports about the company. SVB Leerink downgraded HilleVax from an outperform rating to a market perform rating and cut their price objective for the stock from $28.00 to $2.00 in a research report on Tuesday. Guggenheim downgraded HilleVax from a buy rating to a neutral rating in a research report on Monday. JPMorgan Chase & Co. restated a neutral rating and set a $5.00 price objective (down from $24.00) on shares of HilleVax in a research report on Monday. HC Wainwright restated a neutral rating and set a $2.00 price objective (down from $28.00) on shares of HilleVax in a research report on Tuesday. Finally, Stifel Nicolaus downgraded HilleVax from a buy rating to a hold rating and cut their price objective for the stock from $34.00 to $3.00 in a research report on Tuesday. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat, HilleVax has a consensus rating of Hold and a consensus price target of $9.20.
Get Our Latest Stock Report on HilleVax
HilleVax Price Performance
HilleVax (NASDAQ:HLVX – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.13). As a group, equities analysts forecast that HilleVax will post -3.14 earnings per share for the current fiscal year.
Insider Buying and Selling at HilleVax
In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $15.45, for a total value of $92,700.00. Following the completion of the transaction, the director now directly owns 776,878 shares in the company, valued at approximately $12,002,765.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 12,898 shares of company stock worth $193,766. Insiders own 71.10% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of HLVX. EntryPoint Capital LLC acquired a new position in HilleVax in the 1st quarter valued at $80,000. SG Americas Securities LLC acquired a new position in HilleVax in the 4th quarter valued at $139,000. Tidal Investments LLC acquired a new position in HilleVax in the 1st quarter valued at $207,000. abrdn plc purchased a new stake in shares of HilleVax during the 4th quarter valued at $433,000. Finally, Swiss National Bank grew its stake in shares of HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after buying an additional 7,000 shares during the period. 86.42% of the stock is currently owned by institutional investors and hedge funds.
About HilleVax
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Read More
- Five stocks we like better than HilleVax
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Sales Breakout Sends This Semiconductor Stock to Record High
- How Can Investors Benefit From After-Hours Trading
- Surprise Buying Opportunity on This Dividend Aristocrat
- The 3 Best Retail Stocks to Shop for in August
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.